MAIA Biotechnology

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MAIA and other ETFs, options, and stocks.

About MAIA

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. 

CEO
Vlad Vitoc
CEOVlad Vitoc
Employees
13
Employees13
Headquarters
Chicago, Illinois
HeadquartersChicago, Illinois
Founded
2018
Founded2018
Employees
13
Employees13

MAIA Key Statistics

Market cap
88.14M
Market cap88.14M
Price-Earnings ratio
-3.22
Price-Earnings ratio-3.22
Dividend yield
Dividend yield
Average volume
1.20M
Average volume1.20M
High today
$2.45
High today$2.45
Low today
$2.40
Low today$2.40
Open price
$2.32
Open price$2.32
Volume
13.07K
Volume13.07K
52 Week high
$2.74
52 Week high$2.74
52 Week low
$0.87
52 Week low$0.87

Stock Snapshot

As of today, MAIA Biotechnology(MAIA) shares are valued at $2.41. The company's market cap stands at 88.14M, with a P/E ratio of -3.22.

As of 2026-01-23, MAIA Biotechnology(MAIA) stock has fluctuated between $2.40 and $2.45. The current price stands at $2.41, placing the stock +0.3% above today's low and -1.7% off the high.

The MAIA Biotechnology(MAIA)'s current trading volume is 13.07K, compared to an average daily volume of 1.2M.

In the last year, MAIA Biotechnology(MAIA) shares hit a 52-week high of $2.74 and a 52-week low of $0.87.

In the last year, MAIA Biotechnology(MAIA) shares hit a 52-week high of $2.74 and a 52-week low of $0.87.

People also own

Based on the portfolios of people who own MAIA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.